Image source: Fitbit.
Shares of Fitbit (NYSE:FIT) tumbled 75% in 2016, according to data provided byS&P Global Market Intelligence. Investors weren’t thrilled about heavy spending on R&D knocking down profitability, especially when that spending failed to produce anything other than weak guidance for the fourth quarter.
In an effort to keep up its impressive growth rate, Fitbit began to dramatically increase its spending in 2016. For the first three quarters of the year, total operating expenses more than doubled, with R&D spending soaring by nearly 150%. This spending helped the company launch a number of new products throughout the year, including the Alta, Blaze, Charge 2, and Flex 2.
The downside of this spending was a steep decline in earnings. EPS tumbled more than 60% during the first three quarters of 2016, with revenue not growing fast enough to counteract the massive increase in spending. With a new slate of products, the holiday season was the ultimate test of Fitbit’s strategy. Unfortunately for investors, the company’s guidance was a disappointment.
short term investments: MEI Pharma, Inc.(MEIP)
- [By Chris Lange]
MEI Pharma, Inc. (NASDAQ: MEIP) saw its shares make a solid gain on Thursday after the company received a crucial upgrade from Oppenheimer. Most analysts only issue price targets that are within a range of 5% to 25% for stocks, but this upgrade absolutely blows these small calls out of the water.
short term investments: Farmer Brothers Company(FARM)
- [By Matt Hogan]
Finbox.io fair value data (as of January 4) shows that there are only five US manufacturing stocks that have 25% or more margin of safety: Vera Bradley, Inc. (NASDAQ: VRA), Cooper Tire & Rubber Co (NYSE: CTB), Farmer Brothers Co. (NASDAQ: FARM), Allergan plc Ordinary Shares (NYSE: AGN) and Motorcar Parts of America, Inc. (NASDAQ: MPAA).
short term investments: Coherent, Inc.(COHR)
- [By Lisa Levin]
Shares of Rofin-Sinar Technologies (NASDAQ: RSTI) got a boost, shooting up 37 percent to $31.50 as Coherent, Inc. (NASDAQ: COHR) announced its plans to buy Rofin-Sinar Technologies Inc in a deal valued at around $942 million.
short term investments: DAVIDsTEA Inc.(DTEA)
- [By Monica Gerson]
DavidsTea Inc (NASDAQ: DTEA) is expected to post its quarterly earnings at $0.43 per share on revenue of $71.74 million.
SemiLEDs Corporation (NASDAQ: LEDS) is estimated to post its quarterly earnings.
short term investments: Viking Therapeutics, Inc.(VKTX)
- [By Lisa Levin]
Viking Therapeutics Inc (NASDAQ: VKTX) shares dropped 39 percent to $1.17 after the company priced 7.5 million share offering at $1.25 per share.
- [By Lisa Levin]
DBV Technologies SA – ADR (NASDAQ: DBVT) shares tumbled 50.6 percent to $23.73 after the company disclosed that its peanut allergy trial failed to meet primary endpoint.
Connecture Inc (NASDAQ: CNXR) shares declined 40.8 percent to $0.290. Connecture reported that it will voluntarily delist from the NASDAQ for OTCQX Market.
Walter Investment Management Corp (NYSE: WAC) slipped 19.2 percent to $0.410. On Friday, Walter Investment Management disclosed that it has reached an agreement with term lenders and senior noteholders on financial restructuring.
Eldorado Gold Corp (USA) (NYSE: EGO) shares dropped 15.9 percent to $1.83. Eldorado Gold lowered its production guidance for its Kisladag operation.
Seanergy Maritime Holdings Corp. (NASDAQ: SHIP) shares fell 15.4 percent to $1.04.
Future Fintech Group Inc (NASDAQ: FTFT) dropped 13.6 percent to $1.53. Future FinTech reported filing of proxy statement, including proposal for corporate restructuring.
Concordia International Corp (NASDAQ: CXRX) shares fell 12.3 percent to $0.500 after dipping 38.71 percent on Friday.
Aemetis Inc (NASDAQ: AMTX) shares declined 11.3 percent to $0.550
OncoSec Medical Inc (NASDAQ: ONCS) dipped 10.5 percent to $1.12. OncoSec reported a $7.1 million registered direct at-the-market offering at a price of $1.34375 per share.
Evoke Pharma Inc (NASDAQ: EVOK) shares fell 10.35 percent to $3.08 after the company disclosed 'positive' topline results from comparative exposure pharmacokinetic study for Gimoti.
Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) shares dropped 9.4 percent to $11.60 as the company disclosed Phase 2 interim 24-week data with pegylated interferon lambda in Hepatitis Delta Virus infection at the American Association for the Study of Liver Diseases Meeting.
Viking Therapeutics Inc (NASDAQ: VKTX) shares slipped 6.6 percent to $2.80. Viking Therapeutics presented results from proof-of-concept study of VK0214 in in vivo